Patents by Inventor Dirk WARTENBERG

Dirk WARTENBERG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12338473
    Abstract: Disclosed are genetically engineered microbial cells for the production of oligosaccharides comprising a galactose-?1,4-glucose moiety at their reducing end, wherein said microbial cells are able to produce said oligosaccharides in the absence of exogenously added lactose, and a method of producing said oligosaccharides using said microbial cells.
    Type: Grant
    Filed: June 8, 2023
    Date of Patent: June 24, 2025
    Assignee: Chr. Hansen A/S
    Inventors: Stefan Jennewein, Dirk Wartenberg, Katja Parschat
  • Publication number: 20250154545
    Abstract: Disclosed is a method of inhibiting isomerization of a reducing saccharide in an aqueous solution containing said reducing saccharide upon thermal treatment of said aqueous saccharide solution by acidifying the aqueous saccharide solution prior to its thermal treatment, and the use of the thermally treated aqueous solution containing said reducing saccharide for producing a biological product.
    Type: Application
    Filed: January 16, 2025
    Publication date: May 15, 2025
    Applicant: Chr. Hansen A/S
    Inventor: Dirk WARTENBERG
  • Publication number: 20240318216
    Abstract: The present invention relates to methods for the production of oligosaccharides in genetically modified bacterial host cells, as well as to the genetically modified host cells used in the methods. The genetically modified host cell comprises at least one recombinant glycosyltransferase, and at least one nucleic acid sequence coding for a protein enabling the export of the oligosaccharide.
    Type: Application
    Filed: June 4, 2024
    Publication date: September 26, 2024
    Applicant: Chr. Hansen HMO GmbH
    Inventors: Stefan Jennewein, Dirk Wartenberg
  • Patent number: 12037622
    Abstract: The present invention relates to methods for the production of oligosaccharides in genetically modified bacterial host cells, as well as to the genetically modified host cells used in the methods. The genetically modified host cell comprises at least one recombinant glycosyltransferase, and at least one nucleic acid sequence coding for a protein enabling the export of the oligosaccharide.
    Type: Grant
    Filed: May 18, 2021
    Date of Patent: July 16, 2024
    Assignee: Chr. Hansen HMO GmbH
    Inventors: Stefan Jennewein, Dirk Wartenberg
  • Publication number: 20240200112
    Abstract: The present invention relates to a method for producing fucosylated oligosaccharides by using a recombinant prokaryotic host cell that is cultivated on a gluconeogenic substrate, as well as to the host cell and its use. The host cell is genetically modified in that the activity of a fructose-6-phosphate converting enzyme is abolished or lowered, and the transport of the produced fucosylated oligosaccharide through the cell membrane is facilitated by an exogenous transport protein.
    Type: Application
    Filed: December 21, 2023
    Publication date: June 20, 2024
    Applicant: Chr. Hansen HMO GmbH
    Inventors: Stefan Jennewein, Dirk Wartenberg, Katja Parschat
  • Publication number: 20240110213
    Abstract: Disclosed are genetically engineered microbial cells for the production of an oligosaccharide of interest, wherein said microbial cells possess a variant of the E. coli lactose permease LacY which exhibits a reduced transport activity for lactose, and methods for producing an oligosaccharide by using said genetically engineered microbial cells.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 4, 2024
    Applicant: Chr. Hansen HMO GmbH
    Inventors: Henning Frerigmann, Christian Trötschel, Dirk Wartenberg, Stefan Jennewein
  • Patent number: 11920173
    Abstract: Disclosed are non-naturally-occurring microorganisms for the production of N-acetylneuraminic acid, a method for the production of N-acetylneuraminic acid by fermentation of the non-naturally-occurring microorganisms, and nutritional compositions containing N-acetylneuraminic acid which has been produced by fermentation of the non-naturally-occurring microorganisms.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: March 5, 2024
    Assignee: Chr Hansen HMO GmbH
    Inventors: Stefan Jennewein, Dirk Wartenberg
  • Publication number: 20240052324
    Abstract: Disclosed are enzymes, compositions, genetically engineered cells and methods for the fermentative production of 6?-sialyllactose.
    Type: Application
    Filed: December 22, 2020
    Publication date: February 15, 2024
    Applicant: Chr. Hansen HMO GmbH
    Inventors: Stefan Jennewein, Dirk Wartenberg
  • Patent number: 11898185
    Abstract: The present invention relates to a method for producing fucosylated oligosaccharides by using a recombinant prokaryotic host cell that is cultivated on a gluconeogenic substrate, as well as to the host cell and its use. The host cell is genetically modified in that the activity of a fructose-6-phosphate converting enzyme is abolished or lowered, and the transport of the produced fucosylated oligosaccharide through the cell membrane is facilitated by an exogenous transport protein.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: February 13, 2024
    Assignee: Chr Hansen HMO GmbH
    Inventors: Stefan Jennewein, Dirk Wartenberg, Katja Parschat
  • Publication number: 20230399669
    Abstract: Disclosed are genetically engineered microbial cells for the production of oligosaccharides comprising a galactose-?1,4-glucose moiety at their reducing end, wherein said microbial cells are able to produce said oligosaccharides in the absence of exogenously added lactose, and a method of producing said oligosaccharides using said microbial cells.
    Type: Application
    Filed: June 8, 2023
    Publication date: December 14, 2023
    Applicant: Chr. Hansen HMO GmbH
    Inventors: Stefan Jennewein, Dirk Wartenberg, Katja Parschat
  • Patent number: 11713475
    Abstract: Disclosed are genetically engineered microbial cells for the production of oligosaccharides comprising a galactose-?1,4-glucose moiety at their reducing end, wherein said microbial cells are able to produce said oligosaccharides in the absence of exogenously added lactose, and a method of producing said oligosaccharides using said microbial cells.
    Type: Grant
    Filed: September 2, 2019
    Date of Patent: August 1, 2023
    Assignee: Chr. Hansen HMO GmbH
    Inventors: Stefan Jennewein, Dirk Wartenberg, Katja Parschat
  • Publication number: 20220290198
    Abstract: Disclosed are non-sporulating Bacillus cells for the production of a sialylated oligosaccharide wherein said Bacillus cell has been genetically engineered to possess a lactose permease, a CMP-NeuNAc biosynthesis pathway and a sialyltransferase, as well as a method for producing a sialylated oligosaccharide using said Bacillus cell.
    Type: Application
    Filed: August 10, 2020
    Publication date: September 15, 2022
    Applicant: Chr. Hansen HMO GmbH
    Inventors: Stefan Jennewein, Dirk Wartenberg, Stefanie Habersetzer
  • Publication number: 20220220524
    Abstract: Disclosed are non-sporulating Bacillus cells for the production of a fucosylated oligosaccharide as well as a method for producing a fucosylated oligosaccharide, wherein said Bacillus cell has been genetically engineered to possess a lactose permease, a GDP-fucose biosynthesis pathway and a fucosyltransferase.
    Type: Application
    Filed: June 8, 2020
    Publication date: July 14, 2022
    Inventors: Stefan JENNEWEIN, Dirk WARTENBERG, Stefanie HABERSETZER
  • Publication number: 20220145342
    Abstract: Disclosed are genetically engineered microbial cells for the production of a carbohydrate of interest, wherein the microbial cells possess an increased intracellular availability of at least one sugar phosphate, and produce the carbohydrate of interest when being cultivated in a culture medium containing a mixed monosaccharide feedstock as main carbon and energy source. Also disclosed is a fermentative method of producing a carbohydrate of interest by cultivating said genetically engineered microbial cell in the presence of a mixed monosaccharide feedstock as main carbon and energy source.
    Type: Application
    Filed: February 28, 2020
    Publication date: May 12, 2022
    Inventors: Stefan JENNEWEIN, Dirk WARTENBERG
  • Publication number: 20210363557
    Abstract: Disclosed is a method for the production of a desired oligosaccharide using a genetically-engineered microbial host cell, and said genetically-engineered microbial host cell which has been genetically engineered to express a heterologous glycosidase which is able to intracellularly degrade metabolic saccharide by-products that are generated during the intracellular biosynthesis of the desired oligosaccharide.
    Type: Application
    Filed: May 13, 2019
    Publication date: November 25, 2021
    Inventors: Stefan JENNEWEIN, Dirk WARTENBERG
  • Publication number: 20210317493
    Abstract: Disclosed are genetically engineered microbial cells for the production of oligosaccharides comprising a galactose-?1,4-glucose moiety at their reducing end, wherein said microbial cells are able to produce said oligosaccharides in the absence of exogenously added lactose, and a method of producing said oligosaccharides using said microbial cells.
    Type: Application
    Filed: September 2, 2019
    Publication date: October 14, 2021
    Inventors: Stefan JENNEWEIN, Dirk WARTENBERG, Katja PARSCHAT
  • Publication number: 20210277435
    Abstract: The present invention relates to methods for the production of oligosaccharides in genetically modified bacterial host cells, as well as to the genetically modified host cells used in the methods. The genetically modified host cell comprises at least one recombinant glycosyltransferase, and at least one nucleic acid sequence coding for a protein enabling the export of the oligosaccharide.
    Type: Application
    Filed: May 18, 2021
    Publication date: September 9, 2021
    Inventors: Stefan JENNEWEIN, Dirk WARTENBERG
  • Publication number: 20210277436
    Abstract: The present invention relates to methods for the production of oligosaccharides in genetically modified bacterial host cells, as well as to the genetically modified host cells used in the methods. The genetically modified host cell comprises at least one recombinant glycosyltransferase, and at least one nucleic acid sequence coding for a protein enabling the export of the oligosaccharide.
    Type: Application
    Filed: May 18, 2021
    Publication date: September 9, 2021
    Inventors: Stefan JENNEWEIN, Dirk WARTENBERG
  • Publication number: 20210198709
    Abstract: Disclosed are methods for the fermentative production of a sialylated saccharide and genetically engineered microbial cells for use in said method, wherein the genetically engineered microbial cells comprise (i) a sialic acid biosynthesis pathway comprising a glucosamine-6-phosphate N-acetyltransferase, (ii) a cytidine 5?-monophospho-(CMP)-N-acetylneuraminic acid synthetase; and (iii) a sialyltransferase, for producing sialylated saccharides, as well as the use of said sialylated oligosaccharides for providing nutritional compositions.
    Type: Application
    Filed: May 27, 2019
    Publication date: July 1, 2021
    Inventors: Stefan JENNEWEIN, Dirk WARTENBERG
  • Patent number: 11046985
    Abstract: The present invention relates to methods for the production of oligosaccharides in genetically modified bacterial host cells, as well as to the genetically modified host cells used in the methods. The genetically modified host cell comprises at least one recombinant glycosyltransferase, and at least one nucleic acid sequence coding for a protein enabling the export of the oligosaccharide.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: June 29, 2021
    Inventors: Stefan Jennewein, Dirk Wartenberg